Zotiraciclib Plus Temozolomide Shows Meaningful Efficacy in Recurrent High-Grade Gliomas
February 5th 2021
February 5, 2021 - The potent CDK9 inhibitor zotiraciclib, when used in combination was temozolomide, was found to induce clinically meaningful efficacy with a tolerable safety profile in patients with recurrent, high-grade gliomas.